A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma

Por Rocca, A, Minucci, S, Tosti, G, Croci, D, Contegno, F, Ballarini, M, Nolè, F, Munzone, E, Salmaggi, A, Goldhirsch, A, Pelicci, P G, Testori, A
Publicado em 2009

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Por Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL
Publicado em 2019-04-01

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial

Por Munzone, E., Giobbie-Hurder, A., Gusterson, B. A., Mallon, E., Viale, G., Thürlimann, B., Ejlertsen, B., MacGrogan, G., Bibeau, F., Lelkaitis, G., Price, K. N., Gelber, R. D., Coates, A. S., Goldhirsch, A., Colleoni, M.
Publicado no Ann Oncol (2015)